Skip to main content

AI Bias Analysis

4 models · Takes ~15 seconds

MedPage Today

Targeted Lung Cancer Drug Aces Confirmatory Trial in Frontline Setting

Targeted Lung Cancer Drug Aces Confirmatory Trial in Frontline Setting
ShareXFacebook

(MedPage Today) -- CHICAGO -- An oral targeted drug reduced the risk of disease progression or death by 35% compared with chemotherapy when given as first-line treatment for non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertions...

M

Source

MedPage Today

Read full article at MedPage Today

Opens original article in a new tab

Advertisement

Related Health Stories

Advertisement